This company listing is no longer active
AVEO Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Key information
134.1%
Debt to equity ratio
US$38.68m
Debt
| Interest coverage ratio | n/a |
| Cash | US$77.40m |
| Equity | US$28.85m |
| Total liabilities | US$72.39m |
| Total assets | US$101.23m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: VPA1's short term assets ($100.7M) exceed its short term liabilities ($42.4M).
Long Term Liabilities: VPA1's short term assets ($100.7M) exceed its long term liabilities ($30.0M).
Debt to Equity History and Analysis
Debt Level: VPA1 has more cash than its total debt.
Reducing Debt: VPA1 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VPA1 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: VPA1 has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 12.7% each year.